provided additional evidence to suggest that downregulation of ZEB1 is essential for the LMO2 driven stemness phenotype in T-ALL cells as well as resistance to methotrexate treatment, a chemotherapeutic drug used to treat T-ALL (165). The gene discussed is ZEB1; the disease is acute lymphoblastic leukemia.